Accelerator production routes for therapeutic alpha emitters
55No. 498 in all physics · No. 21 in Medical and Radiation Physics
Determine the optimal production route for Ac-225 and related $\alpha$ emitters by measuring excitation functions and co-produced impurities for proton spallation of thorium-232, photonuclear production from Ra-226, and deuteron or $\alpha$ routes, in the energy ranges used by available accelerators. Key figure of merit: yield per beam hour at required radionuclidic purity, in particular Ac-227 contamination. An answer is cross sections and yields fixing the preferred route.
What would settle it
Measured excitation functions and target tests reporting yield and impurity levels for each route.
Status in the literature
Accelerator routes expanded supply after about 2018 while impurity control and scale-up remained limiting.
No solutions, ideas or subproblems yet.
Details, signature and history
- Kind
- Well-posed question
- Answer
- Value
- Posed
- 2010
- Topic review
- Sgouros, Bodei, McDevitt and Nedrow, Radiopharmaceutical therapy in cancer: clinical advances and challenges, Nature Reviews Drug Discovery, 2020. Link
- Record
- Revision 1 · imported from the seed collection · compiled by AI, not yet reviewed by an editor
Proof
- Fingerprint
- fc9752740fad…
- Public log
- Entry 1,722, in checkpoint 2,123
- In the log by
- Block 969,698, 2026-10-03
This text was in the PubPhys log by that date. The date says nothing about when the problem was first posed.
Comments (0)
Comments are not records: they are not signed, stamped or logged. How comments work
No comments yet.
Sign in to comment.